We are live on ! Find out more
LBRX

LB Pharmaceuticals
LBRX

77 hedge funds and large institutions have $692M invested in LB Pharmaceuticals in 2026 Q1 according to their latest regulatory filings, with 20 funds opening new positions, 31 increasing their positions, 14 reducing their positions, and 10 closing their positions.

New
Increased
Maintained
Reduced
Closed

121% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 14

100% more first-time investments, than exits

New positions opened: 20 | Existing positions closed: 10

25% more capital invested

Capital invested by funds: $552M → $692M (+$141M)

13% more funds holding

Funds holding: 68 → 77 (+9)

0.39% more ownership

Funds ownership: 97.99% → 98.38% (+0.39%)

0% more funds holding in top 10

Funds holding in top 10: 3 → 3 (0)

Holders
77
Holders Change
+9
Holders Change %
+13.24%
% of All Funds
0.95%
Holding in Top 10
3
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
20
Increased
31
Reduced
14
Closed
10
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
CP
Caligan Partners
New York
+$33.2M
2
NCM
Nantahala Capital Management
Connecticut
+$8.72M
3
SSC
Spruce Street Capital
New York
+$8.55M
4
NFGH
Nan Fung Group Holdings
Hong Kong
+$7.63M
5
GPP
Great Point Partners
Connecticut
+$6.92M

Top Sellers

Rank Fund Capital Flow
1
LGM
Logos Global Management
California
-$6.57M
2
Jennison Associates
Jennison Associates
New York
-$6.54M
3
JP Morgan Chase
JP Morgan Chase
New York
-$4.24M
4
Ameriprise
Ameriprise
Minnesota
-$1.97M
5
LF
Longbow Finance
Switzerland
-$1.83M
Name Holding Trade Value Shares
Change 		Change in
Stake
HS
26
HighVista Strategies
Massachusetts
$4.28M +$772K +33,488 +24%
VFT
27
Vanguard Fiduciary Trust
Pennsylvania
$3.88M +$3.63M +157,426 New
Northern Trust
28
Northern Trust
Illinois
$3.81M +$241K +10,432 +7%
IHAM
29
Integral Health Asset Management
New York
$3.7M +$1.15M +50,000 +50%
UBS Group
30
UBS Group
Switzerland
$3.4M +$2.01M +87,219 +172%
Millennium Management
31
Millennium Management
New York
$3.38M +$3.16M +136,966 New
VPM
32
Vanguard Portfolio Management
Pennsylvania
$2.77M +$2.59M +112,497 New
Ameriprise
33
Ameriprise
Minnesota
$2.67M -$1.97M -85,237 -44%
EP
34
Eversept Partners
New York
$2.47M +$2.31M +100,198 New
Russell Investments Group
35
Russell Investments Group
United Kingdom
$1.78M +$1.63M +70,542 +4,626%
BCM
36
Boxer Capital Management
California
$1.73M – – –
Janus Henderson Group
37
Janus Henderson Group
United Kingdom
$1.61M +$1.51M +65,429 New
Wellington Management Group
38
Wellington Management Group
Massachusetts
$1.3M +$1.21M +52,640 New
SC
39
Stempoint Capital
New York
$1.23M +$1.15M +50,000 New
Morgan Stanley
40
Morgan Stanley
New York
$1.17M +$522K +22,639 +92%
Bank of New York Mellon
41
Bank of New York Mellon
New York
$1.12M +$114K +4,940 +12%
ACP
42
Acuta Capital Partners
California
$713K -$24.9K -1,081 -4%
Calamos Advisors
43
Calamos Advisors
Illinois
$593K +$555K +24,063 New
N
44
Nuveen
North Carolina
$566K – – –
Focus Partners Wealth
45
Focus Partners Wealth
Massachusetts
$489K -$6.46K -280 -1%
RhumbLine Advisers
46
RhumbLine Advisers
Massachusetts
$422K +$18.9K +820 +5%
Bank of America
47
Bank of America
North Carolina
$410K -$626K -27,140 -62%
Deutsche Bank
48
Deutsche Bank
Germany
$379K +$47.5K +2,061 +15%
MHC
49
Meyer Handelman Company
New York
$372K +$348K +15,094 New
OM
50
Opaleye Management
Massachusetts
$358K +$335K +14,506 New
1
2
3 4

LBRX Hedge Fund Activity: Q1 2026 in Review

77 of the 8,130 institutional investors tracked by Wall St. Rank reported a position in LB Pharmaceuticals (LBRX) for Q1 2026, worth a combined $692M — up 25% from $552M a quarter earlier.

Buyers outnumbered sellers: 20 funds opened new LBRX positions and 10 closed out — a net gain of 10 holders — while 31 added to existing stakes and 14 trimmed.

The largest buyer was Caligan Partners, opening a new position worth an estimated $33.2M. The largest seller was Logos Global Management, cutting an estimated $6.57M.

  • 77 institutional investors held LB Pharmaceuticals (LBRX) as of Q1 2026, up from 68 in Q4 2025.
  • Funds reported $692M of LB Pharmaceuticals stock for Q1 2026, up 25% quarter-over-quarter.
  • 20 funds opened new LB Pharmaceuticals positions in Q1 2026 and 10 closed out, a net change of +10 holders.
  • The largest LB Pharmaceuticals buyer in Q1 2026 was Caligan Partners, an estimated $33.2M added.
  • The largest LB Pharmaceuticals seller in Q1 2026 was Logos Global Management, an estimated $6.57M sold.

Based on aggregated 13F filings for Q1 2026.